Petter Stromme

Prof. Petter Stromme

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2008 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
GGGregor D. Gilfillan
Gregor D. Gilfillan
KSKaja Kristine Selmer
Kaja Kristine Selmer
IRIngrid Roxrud
Ingrid Roxrud
RSRaffaella Smith
Raffaella Smith
MKMårten Kyllerman
Mårten Kyllerman
PSPetter Stromme
Petter Stromme

27 May 2009 in neurogenetics
Verified
Journal Article
Closed access
PDF file
DMD. Misceo
D. Misceo
MFM. Fannemel
M. Fannemel
TBT. Barøy
T. Barøy
RRR. Roberto
R. Roberto
BTB. Tvedt
B. Tvedt
EFEirik Frengen
Eirik Frengen

20 September 2007 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
OKOivind J. Kanavin
Oivind J. Kanavin
BWBerit Woldseth
Berit Woldseth
EJEgil Jellum
Egil Jellum
BTBjorn Tvedt
Bjorn Tvedt
BABrage Storstein Andresen
Brage Storstein Andresen
PSPetter Stromme
Petter Stromme
2-methylbutyryl-CoA dehydrogenase deficiency or short/branched chain acyl-CoA dehydrogenase deficiency (SBCADD) is caused by a defect in the degradation pathway of the amino acid L-isoleucine.

1 September 2016 in Neuromuscular Disorders
Verified
Journal Article
Open access
CPChristeen Ramane J. Pedurupillay
Christeen Ramane J. Pedurupillay
SASilja S. Amundsen
Silja S. Amundsen
TBTuva Barøy
Tuva Barøy
MRMagnhild Rasmussen
Magnhild Rasmussen
ABAnne Blomhoff
Anne Blomhoff
PSPetter Stromme
Petter Stromme
Biallelic mutations in IGHMBP2 cause spinal muscular atrophy with respiratory distress type 1 (SMARD1) or Charcot-Marie-Tooth type 2S (CMT2S). We report three families variably affected by IGHMBP2 mutations. Patient 1, an 8-year-old boy with two homozygous variants: c.2T>C and c.861C>G, was wheelchair bound due to sensorimotor axonal neuropathy and chronic respiratory failure. Patient 2 and his younger sister, Patient 3, had compound heterozygous variants: c.983_987delAAGAA and c.1478C>T. However, clinical phenotypes differed markedly as the elder with sensorimotor axonal neuropathy had still unaffected respiratory function at 4.5 years, whereas the younger presented as infantile spinal muscular atrophy and died from relentless respiratory failure at 11 months. Patient 4, a 6-year-old girl homozygous for IGHMBP2 c.449+1G>T documented to result in two aberrant transcripts, was wheelchair dependent due to axonal polyneuropathy. The clinical presentation in Patients 1 and 3 were consistent with SMARD1, whereas Patients 2 and 4 were in agreement with CMT2S.

29 November 2016 in Genes
Verified
Journal Article
Open access
PDF file
NSNadia Skauli
Nadia Skauli
SWSean Wallace
Sean Wallace
SCSamuel C. C. Chiang
Samuel C. C. Chiang
TBTuva Barøy
Tuva Barøy
AHAsbjørn Holmgren
Asbjørn Holmgren
DMDoriana Misceo
Doriana Misceo
Biallelic PIGT variants were previously reported in seven patients from three families with Multiple Congenital Anomalies-Hypotonia Seizures Syndrome 3 (MCAHS3), characterized by epileptic encephalopathy, hypotonia, global developmental delay/intellectual disability, cerebral and cerebellar atrophy, craniofacial dysmorphisms, and skeletal, ophthalmological, cardiac, and genitourinary abnormalities. We report a novel homozygous PIGT missense variant c.1079G>T (p.Gly360Val) in two brothers with several of the typical features of MCAHS3, but in addition, pyramidal tract neurological signs. Notably, they are the first patients with MCAHS3 without skeletal, cardiac, or genitourinary anomalies. PIGT encodes a crucial subunit of the glycosylphosphatidylinositol (GPI) transamidase complex, which catalyzes the attachment of proteins to GPI-anchors, attaching the proteins to the cell membrane. In vitro studies in cells from the two brothers showed reduced levels of GPI-anchors and GPI-anchored proteins on the cell surface, supporting the pathogenicity of the novel PIGT variant.

7 January 2013 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
TBTuva Barøy
Tuva Barøy
DMDoriana Misceo
Doriana Misceo
PSPetter Stromme
Petter Stromme
ASAsbjorg Stray-Pedersen
Asbjorg Stray-Pedersen
AHAsbjørn Holmgren
Asbjørn Holmgren
EFEirik Frengen
Eirik Frengen
Background: Nineteen patients with deletions in chromosome 6p22-p24 have been published so far. The syndromic phenotype is varied, and includes intellectual disability, behavioural abnormalities, dysmorphic features and structural organ defects. Heterogeneous deletion breakpoints and sizes (1–17 Mb) and overlapping phenotypes have made the identification of the disease causing genes challenging. We suggest JARID2 and ATXN1, both harbored in 6p22.3, as disease causing genes. Methods and results: We describe five unrelated patients with de novo deletions (0.1-4.8 Mb in size) in chromosome 6p22.3-p24.1 detected by aCGH in a cohort of approximately 3600 patients ascertained for neurodevelopmental disorders. Two patients (Patients 4 and 5) carried non-overlapping deletions that were encompassed by the deletions of the remaining three patients (Patients 1–3), indicating the existence of two distinct dosage sensitive genes responsible for impaired cognitive function in 6p22.3 deletion-patients. The smallest region of overlap (SRO I) in Patients 1–4 (189 kb) included the genes JARID2 and DTNBP1, while SRO II in Patients 1–3 and 5 (116 kb) contained GMPR and ATXN1. Patients with deletion of SRO I manifested variable degrees of cognitive impairment, gait disturbance and distinct, similar facial dysmorphic features (prominent supraorbital ridges, deep set eyes, dark infraorbital circles and midface hypoplasia) that might be ascribed to the haploinsufficiency of JARID2. Patients with deletion of SRO II showed intellectual disability and behavioural abnormalities, likely to be caused by the deletion of ATXN1. Patients 1–3 presented with lower cognitive function than Patients 4 and 5, possibly due to the concomitant haploinsufficiency of both ATXN1 and JARID2. The chromatin modifier genes ATXN1 and JARID2 are likely candidates contributing to the clinical phenotype in 6p22-p24 deletion-patients. Both genes exert their effect on the Notch signalling pathway, which plays an important role in several developmental processes. Conclusions: Patients carrying JARID2 deletion manifested with cognitive impairment, gait disturbance and a characteristic facial appearance, whereas patients with deletion of ATXN1 seemed to be characterized by intellectual disability and behavioural abnormalities. Due to the characteristic facial appearance, JARID2 haploinsufficiency might represent a clinically recognizable neurodevelopmental syndrome.